| Name | Title | Contact Details |
|---|
TYME, Inc. is a pharmaceutical company focused on creating medicines that specialize in using the body’s immune system to treat diseases. The body has the ability to fight off major diseases and heal itself. Tyme is researching a mechanism that it believes may work alongside the body’s immune system to fight Stage IV Metastatic Cancer. Tyme hopes to provide a novel compound for physicians to use in a treatment regimen for patients fighting six major cancers (breast, lung, prostrate, gastric, esophageal and pancreatic cancers) responsible for 62% of the annual cancer deaths in the United States. The SM-88, Tyme’s proprietary compound, is a novel compound that has the potential to alter defenses to oxidative stress and increase free radical availability to the cancer cell. SM-88 is designed to penetrate the living cancer cells and introduce multiple mechanisms to kill the cell. Inducing transfer of electrons in the cancer cells may allow catalyzed external free radicals to react and stress the cell. SM-88 is a combination of low dose agents used for non-cancer treatment.
Zynerba (NASDAQ: ZYNE) is dedicated to improving the lives of people with rare and near rare neuropsychiatric disorders where there is a high unmet medical need by pioneering the development and commercialization of next-generation pharmaceutically-produced cannabinoid therapeutics formulated for transdermal delivery. Cannabinoids interact with specific receptors throughout the body to produce pharmacologic effects, primarily in the CNS and immune systems. Transdermal delivery has the potential to reduce adverse effects associated with oral dosing because it allows the drug to be absorbed through the skin directly into the bloodstream, avoiding the gastrointestinal tract and lessening the opportunity for GI-related adverse events. It also avoids first-pass liver metabolism, potentially enabling lower dosage levels of active pharmaceutical ingredients with a higher bioavailability and an improved safety profile. Zynerba`s lead patent-protected product candidate in clinical development is ZYN002: ZYN002 is the first and only pharmaceutically-produced cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. Through a proprietary combination of our pharmaceutically-produced CBD and permeation enhancers, we believe we can effectively deliver CBD through the layers of the epidermis and into the circulatory system. The company is currently assessing ZYN002 in Fragile X syndrome and certain adult and pediatric refractory epilepsies. These include adult refractory focal epilepsy and developmental and epileptic encephalopathies (DEE), a heterogeneous group of rare and ultra-rare epilepsy syndromes associated with severe cognitive impairment and behavioral disturbances.
Humanetics Corp. is a Eden Prairie, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BioTek Instruments is a worldwide leader in the development of high performance, bioanalytical measurement systems and software. Our representatives worldwide call on a variety of customers including academic, government, and biotech/pharmaceutical. We
Founded in 2011, Intact Vascular located in Wayne, PA is a privately held medical device company that develops minimally invasive peripheral vascular products. The Tack Endovascular System™ is designed to optimize peripheral balloon angioplasty results in the treatment of peripheral artery disease. This technology will offer physicians a new treatment option for treating peripheral artery disease. Intact Vascular is committed to developing safe, efficacious and easy to use products for patients with vascular disease and for the physicians who treat them.